The invention provides non-naturally occurring microbial organisms containing caprolactone pathways having at least one exogenous nucleic acid encoding a butadiene pathway enzyme expressed in a sufficient amount to produce caprolactone. The invention additionally provides methods of using such microbial organisms to produce caprolactone by culturing a non-naturally occurring microbial organism containing caprolactone pathways as described herein under conditions and for a sufficient period of time to produce caprolactone.

The present invention provides for a genetically modified host cell and related methods and materials for the biocatalytic production of an ?,?-dicarboxylic acids (DCAs) and/or mono-methyl ester derivatives of dicarboxylic acids (DCAMMEs).

The present invention provides for a genetically modified host cell and related methods and materials for the biocatalytic production of an ?,?-dicarboxylic acids (DCAs) and/or mono-methyl ester derivatives of dicarboxylic acids (DCAMMEs).

A method for making intermediate compounds suitable for making muscenone, the compositions made by said methods, the various uses of said compositions, and enzyme variants useful in said methods.

A method for making intermediate compounds suitable for making muscenone, the compositions made by said methods, the various uses of said compositions, and enzyme variants useful in said methods.

Provided herein are biosynthetic methods for producing lactones, such as macrocyclic lactones, from fatty acids. The lactones produced using and/or during the biosynthetic methods are also provided.

Provided herein are biosynthetic methods for producing lactones, such as macrocyclic lactones, from fatty acids. The lactones produced using and/or during the biosynthetic methods are also provided.

A Streptomyces antibioticus PPI-16 with the accession number of GDMCC NO: 60970. Active compounds produced thereby can inhibit multiple pathogenic fungi, including Colletrichum orbiculare, Colletotrichum capsica, Tobacco anthracnose, and Candida albicans.

A Streptomyces antibioticus PPI-16 with the accession number of GDMCC NO: 60970. Active compounds produced thereby can inhibit multiple pathogenic fungi, including Colletrichum orbiculare, Colletotrichum capsica, Tobacco anthracnose, and Candida albicans.

The invention relates to a polypeptide for the enzymatic detoxification of zearalenone, said polypeptide being a monooxygenase which converts the keto group in position 7 of zearalenone into an ester group, the monooxygenase in particular being an amino acid sequence selected from the group comprising sequence ID No. 1, 2 and 3 or a functional variant thereof. The functional variant and at least one of the amino acid sequences has a sequence identity of at least 60%, preferably at least 70%, more preferably at least 80% and most preferably 90%,